Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2008

01-02-2008 | Original Article

In vivo biodistribution of an androgen receptor avid PET imaging agent 7-α-fluoro-17 α-methyl-5-α-dihydrotestosterone ([18F]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist

Authors: Sudha Garg, Aniruddha Doke, Kimberly W. Black, Pradeep K. Garg

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2008

Login to get access

Abstract

Purpose

For this study, we have assessed the in vivo distribution and androgen receptor (AR) seeking properties of an F-18-labeled androgen [18F]FMDHT in rats castrated with a GnRH antagonist.

Materials and methods

The radiochemical synthesis of [18F]FMDHT was performed using a previously published method. The radiochemical synthesis provided the desired product in good radiochemical yields and radiochemical purity. In vivo biodistribution studies were performed in chemically castrated rats. The animals were castrated using cetrorelix, a GnRH antagonist. To assess the specificity of [18F]FMDHT towards ARs, a separate group of animals was pretreated with a large dose of androgen before the [18F]FMDHT injection.

Results

The in vivo biodistribution results show selective uptake of [18F]FMDHT in the prostate that ranged from 0.46 + 0.10 %ID/g at 1 h to 0.59 + 0.16 %ID/g at 3 h with prostate to muscle ratio ranging from 8.06 + 2.46 at 1 h to 18.81 + 4.90 at 3 h.

Conclusions

These in vivo distribution studies document a high selectivity and specificity of [18F]FMDHT towards AR rich tissues and suggests that [18F]FMDHT may be a useful in vivo PET imaging ligand.
Literature
1.
go back to reference Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440–8.PubMedCrossRef Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440–8.PubMedCrossRef
3.
go back to reference Garg PK, Labaree DC, Hoyte RM, Hochberg RB. [7a-18F]Fluoro-17a-methyl-5a-dihydrotestosterone: a ligand for androgen receptor-mediated imaging of prostate cancer. Nucl Med Biol 2001;28:85–90.PubMedCrossRef Garg PK, Labaree DC, Hoyte RM, Hochberg RB. [7a-18F]Fluoro-17a-methyl-5a-dihydrotestosterone: a ligand for androgen receptor-mediated imaging of prostate cancer. Nucl Med Biol 2001;28:85–90.PubMedCrossRef
4.
go back to reference Garg PK, Labaree DC, Hoyte RM, Seibyl JP, Hochberg RB. An 18F labeled steroid for androgen receptor mediated imaging of prostate tumors and metasteses. J Labelled Comp Radiopharm 1999;42:S321–3. Garg PK, Labaree DC, Hoyte RM, Seibyl JP, Hochberg RB. An 18F labeled steroid for androgen receptor mediated imaging of prostate tumors and metasteses. J Labelled Comp Radiopharm 1999;42:S321–3.
5.
go back to reference Labaree DC, Hoyte RM, Nazareth LV, Weigel NL, Hochberg RB. 7a-Iodo and fluoro steroids as androgen receptor mediated imaging agents. J Med Chem 1999;42:2021–34.PubMedCrossRef Labaree DC, Hoyte RM, Nazareth LV, Weigel NL, Hochberg RB. 7a-Iodo and fluoro steroids as androgen receptor mediated imaging agents. J Med Chem 1999;42:2021–34.PubMedCrossRef
6.
go back to reference Salameh W, Bhasin S, Steiner B, McAdams LA, Peterson M, Swerdloff R. Marked suppression of gonadotropins and testosterone by an antagonist analog of gonadotropin-releasing hormone in men. Fertil Steril 1991;55:156–64.PubMed Salameh W, Bhasin S, Steiner B, McAdams LA, Peterson M, Swerdloff R. Marked suppression of gonadotropins and testosterone by an antagonist analog of gonadotropin-releasing hormone in men. Fertil Steril 1991;55:156–64.PubMed
7.
go back to reference Klingmuller D, Schepke M, Enzweiler C, Bidlingmaier F. Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol (Copenh) 1993;128:15–8. Klingmuller D, Schepke M, Enzweiler C, Bidlingmaier F. Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol (Copenh) 1993;128:15–8.
8.
go back to reference Garg S, Nichols KB, Black K, Labaree DC, Hochberg RB, Garg PK. Improved radiochemical synthesis and biodistribution of F-18 labeled androgen; [18F]FMDHT. Mol Imaging Biol 2005;7:178. Garg S, Nichols KB, Black K, Labaree DC, Hochberg RB, Garg PK. Improved radiochemical synthesis and biodistribution of F-18 labeled androgen; [18F]FMDHT. Mol Imaging Biol 2005;7:178.
9.
go back to reference Garg PK, Garg S, Zalutsky MR. Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidine. Nuc Med Biol 1994;21:97–103.CrossRef Garg PK, Garg S, Zalutsky MR. Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidine. Nuc Med Biol 1994;21:97–103.CrossRef
10.
go back to reference Dupont A, Labrie F, Giguere M, Borsanyi JP, Lacourciere Y, Bergeron N, et al. Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. Eur J Cancer Clin Oncol 1988;24:659–66.PubMedCrossRef Dupont A, Labrie F, Giguere M, Borsanyi JP, Lacourciere Y, Bergeron N, et al. Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. Eur J Cancer Clin Oncol 1988;24:659–66.PubMedCrossRef
11.
go back to reference Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167:1670–4.PubMedCrossRef Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167:1670–4.PubMedCrossRef
12.
go back to reference Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, et al. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology 1996;137:3430–6.PubMedCrossRef Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, et al. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology 1996;137:3430–6.PubMedCrossRef
13.
go back to reference Lamharzi N, Schally AV, Koppan M. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 1998;77:185–92.PubMedCrossRef Lamharzi N, Schally AV, Koppan M. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 1998;77:185–92.PubMedCrossRef
14.
go back to reference Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA 2004;101:4996–5001.PubMedCrossRef Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA 2004;101:4996–5001.PubMedCrossRef
15.
go back to reference Choe YS, Lidstrom PJ, Chi DY, Bonasera TA, Welch MJ, Katzenellenbogen JA. Synthesis of 11b-[18F]fluoro-5a-dihydrotestosterone and 11b-[18F]fluoro-19-nor-5a-dihydrotestosterone: Preparation via halofluorination-reduction, receptor binding, and tissue distribution. J Med Chem 1995;38:816–25.PubMedCrossRef Choe YS, Lidstrom PJ, Chi DY, Bonasera TA, Welch MJ, Katzenellenbogen JA. Synthesis of 11b-[18F]fluoro-5a-dihydrotestosterone and 11b-[18F]fluoro-19-nor-5a-dihydrotestosterone: Preparation via halofluorination-reduction, receptor binding, and tissue distribution. J Med Chem 1995;38:816–25.PubMedCrossRef
16.
go back to reference Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 1992;33:724–34.PubMed Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 1992;33:724–34.PubMed
17.
go back to reference Liu AJ, Katzenellenbogen JA, VanBrocklin HF, Mathias CJ, Welch MJ. 20-[18F]fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies. J Nucl Med 1991;32:81–8.PubMed Liu AJ, Katzenellenbogen JA, VanBrocklin HF, Mathias CJ, Welch MJ. 20-[18F]fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies. J Nucl Med 1991;32:81–8.PubMed
18.
go back to reference Brandes SJ, Katzenellenbogen JA. Fluorinated androgens and progestins: molecular probes for androgen and progesterone receptors with potential use in positron emission tomography. Mol Pharmacol 1987;32:391–403.PubMed Brandes SJ, Katzenellenbogen JA. Fluorinated androgens and progestins: molecular probes for androgen and progesterone receptors with potential use in positron emission tomography. Mol Pharmacol 1987;32:391–403.PubMed
19.
go back to reference Eagon PK, Seguiti SM, Rogerson BJ, McGuire TF, Porter LE, Seeley DH. Androgen receptor in rat liver: characterization and separation from a male-specific estrogen-binding protein. Arch Biochem Biophys 1989;268:161–75.PubMedCrossRef Eagon PK, Seguiti SM, Rogerson BJ, McGuire TF, Porter LE, Seeley DH. Androgen receptor in rat liver: characterization and separation from a male-specific estrogen-binding protein. Arch Biochem Biophys 1989;268:161–75.PubMedCrossRef
20.
go back to reference Sunahara GI, Finlayson MJ, Warren BL, Bellward GD. Characterization studies of a rat hepatic cytosolic androgen-binding protein. Can J Physiol Pharmacol 1985;63:952–7.PubMed Sunahara GI, Finlayson MJ, Warren BL, Bellward GD. Characterization studies of a rat hepatic cytosolic androgen-binding protein. Can J Physiol Pharmacol 1985;63:952–7.PubMed
21.
go back to reference Fishman RB, Chism L, Firestone GL, Breedlove SM. Evidence for androgen receptors in sexually dimorphic perineal muscles of neonatal male rats. Absence of androgen accumulation by the perineal motoneurons. J Neurobiol 1990;21:694–704.PubMedCrossRef Fishman RB, Chism L, Firestone GL, Breedlove SM. Evidence for androgen receptors in sexually dimorphic perineal muscles of neonatal male rats. Absence of androgen accumulation by the perineal motoneurons. J Neurobiol 1990;21:694–704.PubMedCrossRef
22.
go back to reference Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de la Taille A, Ackermann R, et al. The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (review). Int J Oncol 2003;23:1095–102.PubMed Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de la Taille A, Ackermann R, et al. The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (review). Int J Oncol 2003;23:1095–102.PubMed
23.
go back to reference Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001;61:423–7.PubMed Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001;61:423–7.PubMed
24.
go back to reference Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 2005;63:19–28.PubMedCrossRef Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 2005;63:19–28.PubMedCrossRef
Metadata
Title
In vivo biodistribution of an androgen receptor avid PET imaging agent 7-α-fluoro-17 α-methyl-5-α-dihydrotestosterone ([18F]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist
Authors
Sudha Garg
Aniruddha Doke
Kimberly W. Black
Pradeep K. Garg
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0610-3

Other articles of this Issue 2/2008

European Journal of Nuclear Medicine and Molecular Imaging 2/2008 Go to the issue